Rates, Timing, and Predictors of Retreatment Across Risk-Cohorts in Retinopathy of Prematurity: Intravitreal…

Cohort studyAmerican journal of ophthalmology· Jun 2026

Rates, Timing, and Predictors of Retreatment Across Risk-Cohorts in Retinopathy of Prematurity: Intravitreal Bevacizumab Injection Versus Laser.

Francisco Altamirano, Melissa Yuan, Celine Chaaya … Nimesh A Patel

Pediatric OphthalmologyCohort studyTreatmentQ1IF 4.2

Bevacizumab was associated with lower odds of retinopathy of prematurity retreatment than laser.

Rates, Timing, and Predictors of Retreatment Across Risk-Cohorts in Retinopathy of Prematurity: Intravitreal Bevacizumab Injection Versus Laser.

Francisco Altamirano … Nimesh A Patel

American journal of ophthalmology · Jun 2026 · Q1 in Ophthalmology

Purpose

To characterize rates, timing, and predictors of retinopathy of prematurity (retinopathy of prematurity) retreatment among infants treated with primary laser or intravitreal bevacizumab injection.

Methods

Infants who underwent initial treatment for treatment-warranted retinopathy of prematurity (TW-retinopathy of prematurity) with either intravitreal bevacizumab or laser photocoagulation between 2017 and 2023.

n = 122 infants

Results

bevacizumab-treated infants were far less likely to need retreatment

OR 0.23 (95% CI 0.06 to 0.82)

null 1

0.06

0.82

CI excludes the null - significant

More results

Sixteen (8.8%) required early retreatment at a median postmenstrual age (postmenstrual age) of 40.4 weeks (IQR, 38.44-43.3).

There were differences in the proportion of early retreated infants (21.5% for laser vs 1.7% for injection, P < .001).

More results

The median postmenstrual age at late retreatment was 45.6 weeks (IQR, 43.7-47.4).

Similarly, patients in the bevacizumab group had lower odds of requiring early retreatment compared to those with laser (OR, 0.08; 95% CI, 0.04-0.18).

“

Conclusion · 1 of 3

In this study, early retreatment was low (8.8%), with most eyes initially treated with laser (21.5%) rather than bevacizumab (1.7%).

Conclusion · 2 of 3

Aggressive retinopathy of prematurity was associated with earlier retreatment, highlighting its role as a marker of more severe disease.

Conclusion · 3 of 3

Compared to laser, bevacizumab was associated with lower overall and early retreatment, and delayed need for additional intervention when necessary.

Rates, Timing, and Predictors of Retreatment Across Risk-Cohorts in Retinopathy of Prematurity: Intravitreal Bevacizumab Injection Versus Laser.

Rates, Timing, and Predictors of Retreatment Across Risk-Cohorts in Retinopathy of Prematurity: Intravitreal Bevacizumab Injection Versus Laser.

Related papers